Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri
Boswellic acids are the main well-known active components of the resin of Boswellia carteri (Burseraceae) and these are still dealing with the ethnomedicinal use for the treatment of rheumatoid arthritis and other inflammatory diseases. Although several studies have already been reported on the phar...
Saved in:
Published in | Journal of ethnopharmacology Vol. 107; no. 2; pp. 249 - 253 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Shannon
Elsevier Ireland Ltd
19.09.2006
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Boswellic acids are the main well-known active components of the resin of
Boswellia carteri (Burseraceae) and these are still dealing with the ethnomedicinal use for the treatment of rheumatoid arthritis and other inflammatory diseases. Although several studies have already been reported on the pharmacological properties, especially on the anti-inflammatory activity, of
Boswellia carteri resin and boswellic acids, the ethnomedicinal importance of
Boswellia carteri and its components, boswellic acids, prompted us to undertake detailed investigation on the constituents of the resin and their anti-inflammatory activity. Fifteen triterpene acids, viz., seven of the β-boswellic acids (ursane-type) (
1–
7), two of the α-boswellic acids (oleanane-type) (
8,
9), two of the lupeolic acids (lupane-type) (
10,
11), and four of the tirucallane-type (
12–
14,
16), along with two cembrane-type diterpenes (
17,
18), were isolated and identified from the methanol extract of the resin of
Boswellia carteri. Upon evaluation of 17 compounds,
1–
14 and
16–
18, and compound
15, semi-synthesized from
14 by acetylation, for their inhibitory activity against 12-
O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation (1
μg/ear) in mice, all of the compounds, except for
18, exhibited marked anti-inflammatory activity with a 50% inhibitory dose (ID
50) of 0.05–0.49
mg/ear. |
---|---|
Bibliography: | http://dx.doi.org/10.1016/j.jep.2006.03.006 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0378-8741 1872-7573 |
DOI: | 10.1016/j.jep.2006.03.006 |